SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-285246
Filing Date
2023-11-29
Accepted
2023-11-29 16:54:53
Documents
18
Period of Report
2023-11-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d550515d8k.htm   iXBRL 8-K 38347
2 EX-1.1 d550515dex11.htm EX-1.1 211165
3 EX-5.1 d550515dex51.htm EX-5.1 8445
4 EX-99.1 d550515dex991.htm EX-99.1 11198
8 GRAPHIC g550515g1129103740388.jpg GRAPHIC 1649
9 GRAPHIC g550515g1129103802633.jpg GRAPHIC 3026
10 GRAPHIC g550515g1129110248616.jpg GRAPHIC 5840
  Complete submission text file 0001193125-23-285246.txt   480099

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA verv-20231128.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20231128_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20231128_pre.xml EX-101.PRE 11708
12 EXTRACTED XBRL INSTANCE DOCUMENT d550515d8k_htm.xml XML 3469
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 231453045
SIC: 2834 Pharmaceutical Preparations